PURPOSE OF REVIEW: To compare and contrast the evidence for the effect of glucose control on the prevention of neuropathy in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). RECENT FINDINGS: In T1DM, multiple clinical trials have demonstrated a large benefit from enhanced glucose control, whereas the benefit in T2DM is much more modest. Epidemiologic and laboratory evidence exists to support factors other than hyperglycemia in the development of neuropathy including obesity, hypertension, dyslipidemia, inflammation, and insulin resistance. SUMMARY: T1DM neuropathy and T2DM neuropathy are fundamentally different. In T1DM, glucose control has a large effect on the prevention of neuropathy; therefore, future efforts should continue to concentrate on this avenue of treatment. In contrast, in T2DM, glucose control has a small effect on the prevention of neuropathy; as a result, more research is needed to define the underlying mechanisms for the development of neuropathy. Understanding these mechanisms may lead to novel therapeutic approaches to prevent or treat diabetic neuropathy.
PURPOSE OF REVIEW: To compare and contrast the evidence for the effect of glucose control on the prevention of neuropathy in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). RECENT FINDINGS: In T1DM, multiple clinical trials have demonstrated a large benefit from enhanced glucose control, whereas the benefit in T2DM is much more modest. Epidemiologic and laboratory evidence exists to support factors other than hyperglycemia in the development of neuropathy including obesity, hypertension, dyslipidemia, inflammation, and insulin resistance. SUMMARY:T1DM neuropathy and T2DM neuropathy are fundamentally different. In T1DM, glucose control has a large effect on the prevention of neuropathy; therefore, future efforts should continue to concentrate on this avenue of treatment. In contrast, in T2DM, glucose control has a small effect on the prevention of neuropathy; as a result, more research is needed to define the underlying mechanisms for the development of neuropathy. Understanding these mechanisms may lead to novel therapeutic approaches to prevent or treat diabetic neuropathy.
Authors: K Dahl-Jørgensen; O Brinchmann-Hansen; K F Hanssen; T Ganes; P Kierulf; E Smeland; L Sandvik; O Aagenaes Journal: Br Med J (Clin Res Ed) Date: 1986-11-08
Authors: R R Holman; T L Dornan; V Mayon-White; J Howard-Williams; C Orde-Peckar; L Jenkins; J Steemson; R Rolfe; B Smith; D Barbour; K McPherson; P Poon; C Rizza; J I Mann; A H Knight; A J Bron; R C Turner Journal: Lancet Date: 1983-01-29 Impact factor: 79.321
Authors: Peter J Dyck; James W Albers; Henning Andersen; Joseph C Arezzo; Geert-Jan Biessels; Vera Bril; Eva L Feldman; William J Litchy; Peter C O'Brien; James W Russell Journal: Diabetes Metab Res Rev Date: 2011-10 Impact factor: 4.876
Authors: N Azad; N V Emanuele; C Abraira; W G Henderson; J Colwell; S R Levin; F Q Nuttall; J P Comstock; C T Sawin; C Silbert; F A Rubino Journal: J Diabetes Complications Date: 1999 Sep-Dec Impact factor: 2.852
Authors: Ryan B Griggs; Diogo F Santos; Don E Laird; Suzanne Doolen; Renee R Donahue; Caitlin R Wessel; Weisi Fu; Ghanshyam P Sinha; Pingyuan Wang; Jia Zhou; Sebastian Brings; Thomas Fleming; Peter P Nawroth; Keiichiro Susuki; Bradley K Taylor Journal: Neurobiol Dis Date: 2019-02-23 Impact factor: 5.996
Authors: Amy E Rumora; Giovanni LoGrasso; John M Hayes; Faye E Mendelson; Maegan A Tabbey; Julia A Haidar; Stephen I Lentz; Eva L Feldman Journal: J Neurosci Date: 2019-03-18 Impact factor: 6.167
Authors: Amy E Rumora; Stephen I Lentz; Lucy M Hinder; Samuel W Jackson; Andrew Valesano; Gideon E Levinson; Eva L Feldman Journal: FASEB J Date: 2017-09-13 Impact factor: 5.191